Skip to content

Avance clinical client news: XWPharma initiates first-in-human studies of XW10508, in development for fast-acting relief of treatment-resistant depression and chronic pain

By Gold Cross - October 20, 2021

This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

,

We stand ready to help more patients

Gold Cross | November 29, 2023
,

New Board members at National Rural Health Alliance

Gold Cross | November 29, 2023
,

Premier Chris Minns expands pharmacy trial as 6000 women bypass GPs for over-the-counter consults

Gold Cross | November 28, 2023
, ,

Gold Cross parts ways with Kings Transport

Gold Cross | November 28, 2023
BD Rowa automation gives you back 6 hours in your day

Latest Posts

We stand ready to help more patients
Gold Cross | November 29, 2023
New Board members at National Rural Health Alliance
Gold Cross | November 29, 2023
Premier Chris Minns expands pharmacy trial as 6000 women bypass GPs for over-the-counter consults
Gold Cross | November 28, 2023

Featured Posts

Gold Cross parts ways with Kings Transport
Gold Cross | November 28, 2023
Cost of living now costing our health
Gold Cross | November 21, 2023
Pharmacy firsts
Gold Cross | November 17, 2023

Tags

Scroll To Top